MedTrace Logo

Efficacy of TECAR Therapy in Patients With Fibromyalgia

NCT07769177 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2026-08-17

No results posted yet for this study

Summary

A total of 46 patients aged 18-65 years diagnosed with fibromyalgia according to the 2016 ACR criteria, whose most painful region was axial (neck, back, or lower back), were included in the study and randomly assigned upon admission into treatment ($n=23$) and sham control ($n=23$) groups. The treatment group received real TECAR therapy using the BTL-6000 TR Therapy Pro device for a total of 6 sessions over 3 weeks at a frequency of 2 days per week (each 30-minute session consisting of 10 minutes of capacitive and 5 minutes of resistive modes applied to each of the 2 most painful regions), while the control group underwent the exact same protocol applied as sham therapy at 1% power in pulsed mode.

Conditions

  • Fibromyalgia (FM) OR Fibromyalgia Syndrome

Interventions

DEVICE

TECAR Therapy

TECAR therapy will be applied to the 2 most painful regions, 2 days per week for a total of 6 sessions. Each session will consist of 10 minutes of capacitive mode followed by 5 minutes of resistive mode

DEVICE

Sham TECAR Therapy

Sham TECAR therapy will be applied to ionizing/similar protocol to the 2 most painful regions, 2 days per week for a total of 6 sessions, using 1% power in pulsed mode.

Sponsors & Collaborators

  • Ankara City Hospital Bilkent

    lead OTHER

Principal Investigators

  • SELAMI AKKUS, Prof. Dr. · Ankara Yildirim Beyazıt University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-07
Primary Completion
2026-04-07
Completion
2026-06-15

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07769177 on ClinicalTrials.gov